Cambridge Cognition Holdings plc (AIM: COG) has demonstrated significant progress in their strategy of combing the sale of CATAB™ cognitive assessments with electronic clinical outcome assessments (eCOA), by winning is a contract for three phase II studies with a new pharmaceutical client (the "Client").
Shares have jumped 13% on the back of these contract wins.
The studies announced today have a combined value of £1.37m and are expected to take two years with the objective of tracking early cognitive changes and motor signals associated with the drug being delivered.
The company is providing a single vendor solution for all three studies, managing the procurement of licences, device provision, CANTABTM cognitive assessments, a centralised platform for data acquisition and storage, as well as trial management services. By delivering CANTABTM cognitive assessments and eCOA questionnaires and scales all one platform, the Client will be able to sensitively, efficiently and securely monitor three distinct clinical populations.
Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:
"We are pleased to welcome another pharmaceutical partner to our growing client base, using our innovative digital health technologies. This is the second partnership that has been secured on the strength of launching our enhanced eCOA solution in 2019; underlining the importance of continuing to invest in developing our digital solutions."